Stress response factors as hub-regulators of microRNA biogenesis: implication to the diseased heart

Cell Biochemistry and Function

Volumn , Issue , 2015, Pages 509-518

  Gurianova, Veronika ^a   Stroy, Dmytro ^a   Ciccocioppo, Rachele ^b   Gasparova, Iveta ^c   Petrovic, Daniel ^d   Soucek, Miroslav ^e   Dosenko, Victor ^a   Kruzliak, Peter ^e,f,g  

^a BOGOMOLETZ INSTITUTE OF PHYSIOLOGY   (Ukraine)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

^e ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^f Faculty of Natural Sciences   (Slovakia)

^g UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

Author keywords

cardiac pathophysiology; hub mechanisms; miRNAs biogenesis; stress response

Indexed keywords

MICRORNA;

ALTERNATIVE RNA SPLICING; BIOGENESIS; CARDIOVASCULAR FUNCTION; CELLULAR STRESS RESPONSE; HEART DISEASE; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN SYNTHESIS; REVIEW; RNA EDITING;

EID: 84984600083     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.3151     Document Type: Review

References (162)

1. Fiedler J, Thum T. MicroRNAs in myocardial infarction. Arterioscler Thromb Vasc Biol 2013; 33: 201–205.
2. Kukreja RC, Yin C, Salloum FN. MicroRNAs: new players in cardiac injury and protection. Mol Pharmacol 2011; 80: 558–564.
3. Lorenzen JM, Batkai S, Thum T. Regulation of cardiac and renal ischemia-reperfusion injury by microRNAs. Free Radic Biol Med 2013; 64: 78–84.
4. Novák J, Kružliak P, Bienertová-Vašků J, Slabý O, Novák M. MicroRNA-206: a promising theranostic marker. Theranostics 2014; 4: 119–33.
5. Olson EN. MicroRNAs as therapeutic targets and biomarkers of cardiovascular disease. Sci Transl Med 2014; 6: 239ps33.
6. Salloum FN, Yin C, Kukreja RC. Role of microRNAs in cardiac preconditioning. J Cardiovasc Pharmacol 2010; 56: 581–588.
7. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature 2011; 469: 336–342.
8. Ye Y, Perez-Polo JR, Qian J, Birnbaum Y. The role of microRNA in modulating myocardial ischemia-reperfusion injury. Physiol Genomics 2011; 43: 534–542.
9. Yu S, Li G. MicroRNA expression and function in cardiac ischemic injury. J Cardiovasc Transl Res 2010; 3: 241–245.
10. Zhu H, Fan GC. Role of microRNAs in the reperfused myocardium towards post-infarct remodelling. Cardiovasc Res 2012; 94: 284–292.
11. van Rooij E, Purcell AL, Levin AA. Developing microRNA therapeutics. Circ Res 2012; 110: 496–507.
12. Yang B, Lin H, Xiao J, et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 2007; 13: 486–491.
13. Lu Y, Zhang Y, Shan H, et al. MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: a new mechanism for ischaemic cardioprotection. Cardiovasc Res 2009; 84: 434–441.
14. He B, Xiao J, Ren AJ, et al. Role of miR-1 and miR-133a in myocardial ischemic postconditioning. J Biomed Sci 2011; 18: 22.
15. Pan Z, Sun X, Ren J, et al. miR-1 exacerbates cardiac ischemia-reperfusion injury in mouse models. PLoS One 2012; 7: e50515.
16. Adam O, Lohfelm B, Thum T, et al. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol 2012; 107: 278.
17. Cardin S, Guasch E, Luo X, et al. Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure. Circ Arrhythm Electrophysiol 2012; 5: 1027–1035.
18. Dong S, Cheng Y, Yang J, et al. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem 2009; 284: 29514–29525.
19. Cheng Y, Zhu P, Yang J, et al. Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4. Cardiovasc Res 2010; 87: 431–439.
20. Mukhopadhyay P, Das S, Ahsan MK, Otani H, Das DK. Modulation of microRNA 20b with resveratrol and longevinex is linked with their potent anti-angiogenic action in the ischaemic myocardium and synergestic effects of resveratrol and gamma-tocotrienol. J Cell Mol Med 2012; 16: 2504–2517.
21. Mukhopadhyay P, Mukherjee S, Ahsan K, Bagchi A, Pacher P, Das DK. Restoration of altered microRNA expression in the ischemic heart with resveratrol. PLoS One 2010; 5: e15705.
22. Patrick DM, Montgomery RL, Qi X, et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest 2010; 120: 3912–3916.
23. Qian L, Van Laake LW, Huang Y, Liu S, Wendland MF, Srivastava D. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J Exp Med 2011; 208: 549–560.
24. Wang J, Huang W, Xu R, et al. MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J Cell Mol Med 2012; 16: 2150–2160.
25. van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 2008; 105: 13027–13032.
26. Ye Y, Hu Z, Lin Y, Zhang C, Perez-Polo JR. Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc Res 2010; 87: 535–544.
27. Port JD, Walker LA, Polk J, Nunley K, Buttrick PM, Sucharov CC. Temporal expression of miRNAs and mRNAs in a mouse model of myocardial infarction. Physiol Genomics 2011; 43: 1087–1095.
28. Bauersachs J, Thum T. Biogenesis and regulation of cardiovascular microRNAs. Circ Res 2011; 109: 334–347.
29. Minamino T, Kitakaze M. ER stress in cardiovascular disease. J Mol Cell Cardiol 2010; 48: 1105–1110.
30. Minamino T, Komuro I, Kitakaze M. Endoplasmic reticulum stress as a therapeutic target in cardiovascular disease. Circ Res 2010; 107: 1071–1082.
31. Groenendyk J, Sreenivasaiah PK, Kim do H, Agellon LB, Michalak M. Biology of endoplasmic reticulum stress in the heart. Circ Res 2010; 107: 1185–1197.
32. Kruzliak P, Novák J, Novák M, Fodor GJ. Role of calprotectin in cardiometabolic diseases. Cytokine Growth Factor Rev 2014; 25: 67–75.
33. Smith R, Kruzliak P, Adamcikova Z, Zulli A. Role of Nox inhibitors plumbagin, ML090 and gp91ds-tat peptide on homocysteine thiolactone induced blood vessel dysfunction. Clin Exp Pharmacol Physiol 2015 May 22. doi:10.1111/1440-1681.12427.
34. Finnegan EF, Pasquinelli AE. MicroRNA biogenesis: regulating the regulators. Crit Rev Biochem Mol Biol 2013; 48: 51–68.
35. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003; 425: 415–419.
36. Yeom KH, Lee Y, Han J, Suh MR, Kim VN. Characterization of DGCR8/Pasha, the essential cofactor for Drosha in primary miRNA processing. Nucleic Acids Res 2006; 34: 4622–4629.
37. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 2004; 18: 3016–3027.
38. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, Shiekhattar R. The Microprocessor complex mediates the genesis of microRNAs. Nature 2004; 432: 235–240.
39. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 2002; 21: 4663–4670.
40. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science 2004; 303: 95–98.
41. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001; 409: 363–366.
42. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003; 17: 3011–3016.
43. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 2011; 12: 99–110.
44. Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet 2012; 13: 271–282.
45. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell 2012; 148: 1172–1187.
46. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010; 465: 1033–1038.
47. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 2011; 146: 353–358.
48. Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2013; 495: 333–338.
49. Cheng TL, Wang Z, Liao Q, et al. MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex. Dev Cell 2014; 28: 547–560.
50. Lewis JD, Meehan RR, Henzel WJ, et al. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 1992; 69: 905–914.
51. Nan X, Meehan RR, Bird A. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res 1993; 21: 4886–4892.
52. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393: 386–389.
53. Diaz de Leon-Guerrero S, Pedraza-Alva G, Perez-Martinez L. In sickness and in health: the role of methyl-CpG binding protein 2 in the central nervous system. Eur J Neurosci 2011; 33: 1563–1574.
54. Maunakea AK, Chepelev I, Cui K, Zhao K. Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition. Cell Res 2013; 23: 1256–1269.
55. Young JI, Hong EP, Castle JC, et al. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc Natl Acad Sci U S A 2005; 102: 17551–17558.
56. Bracaglia G, Conca B, Bergo A, et al. Methyl-CpG-binding protein 2 is phosphorylated by homeodomain-interacting protein kinase 2 and contributes to apoptosis. EMBO Rep 2009; 10: 1327–1333.
57. Chahrour M, Zoghbi HY. The story of Rett syndrome: from clinic to neurobiology. Neuron 2007; 56: 422–437.
58. Alvarez-Saavedra M, Carrasco L, Sura-Trueba S, et al. Elevated expression of MeCP2 in cardiac and skeletal tissues is detrimental for normal development. Hum Mol Genet 2010; 19: 2177–2190.
59. McCauley MD, Wang T, Mike E, et al. Pathogenesis of lethal cardiac arrhythmias in Mecp2 mutant mice: implication for therapy in Rett syndrome. Sci Transl Med 2011; 3: 113ra125.
60. Acampa M, Guideri F. Cardiac disease and Rett syndrome. Arch Dis Child 2006; 91: 440–443.
61. Wada T, Kikuchi J, Furukawa Y. Histone deacetylase 1 enhances microRNA processing via deacetylation of DGCR8. EMBO Rep 2012; 13: 142–149.
62. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009; 10: 32–42.
63. Tang X, Wen S, Zheng D, et al. Acetylation of drosha on the N-terminus inhibits its degradation by ubiquitination. PLoS One 2013; 8: e72503.
64. Barr I, Smith AT, Chen Y, Senturia R, Burstyn JN, Guo F. Ferric, not ferrous, heme activates RNA-binding protein DGCR8 for primary microRNA processing. Proc Natl Acad Sci U S A 2012; 109: 1919–1924.
65. Faller M, Matsunaga M, Yin S, Loo JA, Guo F. Heme is involved in microRNA processing. Nat Struct Mol Biol 2007; 14: 23–29.
66. Senturia R, Laganowsky A, Barr I, Scheidemantle BD, Guo F. Dimerization and heme binding are conserved in amphibian and starfish homologues of the microRNA processing protein DGCR8. PLoS One 2012; 7: e39688.
67. Weitz SH, Gong M, Barr I, Weiss S, Guo F. Processing of microRNA primary transcripts requires heme in mammalian cells. Proc Natl Acad Sci U S A 2014; 111: 1861–1866.
68. Kang SJ, Lee C, Kruzliak P. Effects of serum bilirubin on atherosclerotic processes. Ann Med 2014; 46: 138–47.
69. Foresti R, Goatly H, Green CJ, Motterlini R. Role of heme oxygenase-1 in hypoxia-reoxygenation: requirement of substrate heme to promote cardioprotection. Am J Physiol Heart Circ Physiol 2001; 281: H1976–1984.
70. Collino M, Pini A, Mugelli N, et al. Beneficial effect of prolonged heme oxygenase 1 activation in a rat model of chronic heart failure. Dis Model Mech 2013; 6: 1012–1020.
71. Lakkisto P, Csonka C, Fodor G, et al. The heme oxygenase inducer hemin protects against cardiac dysfunction and ventricular fibrillation in ischaemic/reperfused rat hearts: role of connexin 43. Scand J Clin Lab Invest 2009; 69: 209–218.
72. Kozakowska M, Ciesla M, Stefanska A, et al. Heme oxygenase-1 inhibits myoblast differentiation by targeting myomirs. Antioxid Redox Signal 2012; 16: 113–127.
73. Gong M, Chen Y, Senturia R, Ulgherait M, Faller M, Guo F. Caspases cleave and inhibit the microRNA processing protein DiGeorge Critical Region 8. Protein Sci 2012; 21: 797–808.
74. Matskevich AA, Moelling K. Stimuli-dependent cleavage of Dicer during apoptosis. Biochem J 2008; 412: 527–534.
75. Ghodgaonkar MM, Shah RG, Kandan-Kulangara F, et al. Abrogation of DNA vector-based RNAi during apoptosis in mammalian cells due to caspase-mediated cleavage and inactivation of Dicer-1. Cell Death Differ 2009; 16: 858–868.
76. Bandara V, Michael MZ, Gleadle JM. Hypoxia represses microRNA biogenesis proteins in breast cancer cells. BMC Cancer 2014; 14: 533.
77. Ho JJD, Metcalf JL, Yan MS, et al. Functional importance of Dicer protein in the adaptive cellular response to hypoxia. J Biol Chem 2012; 287: 29003–29020.
78. Wiesen JL, Tomasi TB. Dicer is regulated by cellular stresses and interferons. Mol Immunol 2009; 46: 1222–1228.
79. Bhattacharyya SN, Habermacher R, Martine U, Closs EI, Filipowicz W. Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell 2006; 125: 1111–1124.
80. Nallamshetty S, Chan SY, Loscalzo J. Hypoxia: a master regulator of microRNA biogenesis and activity. Free Radic Biol Med 2013; 64: 20–30.
81. Chen JF, Murchison EP, Tang R, et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci U S A 2008; 105: 2111–2116.
82. da Costa Martins PA, Bourajjaj M, Gladka M, et al. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 2008; 118: 1567–1576.
83. Rao PK, Toyama Y, Chiang HR, et al. Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ Res 2009; 105: 585–594.
84. Dincbas-Renqvist V, Pepin G, Rakonjac M, et al. Human Dicer C-terminus functions as a 5-lipoxygenase binding domain. Biochim Biophys Acta 1789; 2009: 99–108.
85. Lisovyy OO, Dosenko VE, Nagibin VS, et al. Cardioprotective effect of 5-lipoxygenase gene (ALOX5) silencing in ischemia-reperfusion. Acta Biochim Pol 2009; 56: 687–694.
86. Lugli G, Larson J, Martone ME, Jones Y, Smalheiser NR. Dicer and eIF2c are enriched at postsynaptic densities in adult mouse brain and are modified by neuronal activity in a calpain-dependent manner. J Neurochem 2005; 94: 896–905.
87. Khalil PN, Neuhof C, Huss R, et al. Calpain inhibition reduces infarct size and improves global hemodynamics and left ventricular contractility in a porcine myocardial ischemia/reperfusion model. Eur J Pharmacol 2005; 528: 124–131.
88. Parameswaran S, Sharma RK. Altered expression of calcineurin, calpain, calpastatin and HMWCaMBP in cardiac cells following ischemia and reperfusion. Biochem Biophys Res Commun 2014; 443: 604–609.
89. Takeshita D, Tanaka M, Mitsuyama S, et al. A new calpain inhibitor protects left ventricular dysfunction induced by mild ischemia-reperfusion in in situ rat hearts. J Physiol Sci 2013; 63: 113–123.
90. Johnston M, Geoffroy MC, Sobala A, Hay R, Hutvagner G. HSP90 protein stabilizes unloaded argonaute complexes and microscopic P-bodies in human cells. Mol Biol Cell 2010; 21: 1462–1469.
91. Pare JM, Tahbaz N, Lopez-Orozco J, LaPointe P, Lasko P, Hobman TC. Hsp90 regulates the function of argonaute 2 and its recruitment to stress granules and P-bodies. Mol Biol Cell 2009; 20: 3273–3284.
92. Latchman DS. Heat shock proteins and cardiac protection. Cardiovasc Res 2001; 51: 637–646.
93. Whitesell L, Bagatell R, Falsey R. The stress response: implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets 2003; 3: 349–358.
94. Takemura G, Kanamori H, Goto K, et al. Autophagy maintains cardiac function in the starved adult. Autophagy 2009; 5: 1034–1036.
95. Nakai A, Yamaguchi O, Takeda T, et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 2007; 13: 619–624.
96. Gibbings D, Mostowy S, Jay F, Schwab Y, Cossart P, Voinnet O. Selective autophagy degrades DICER and AGO2 and regulates miRNA activity. Nat Cell Biol 2012; 14: 1314–1321.
97. Gibbings D, Mostowy S, Voinnet O. Autophagy selectively regulates miRNA homeostasis. Autophagy 2013; 9: 781–783.
98. Dutta D, Xu J, Kim JS, Dunn WA, Jr, Leeuwenburgh C. Upregulated autophagy protects cardiomyocytes from oxidative stress-induced toxicity. Autophagy 2013; 9: 328–344.
99. Skommer J, Rana I, Marques FZ, Zhu W, Du Z, Charchar FJ. Small molecules, big effects: the role of microRNAs in regulation of cardiomyocyte death. Cell Death Dis 2014; 5 e1325.
100. Zhao Y, Xue T, Yang X, et al. Autophagy plays an important role in sunitinib-mediated cell death in H9c2 cardiac muscle cells. Toxicol Appl Pharmacol 2010; 248: 20–27.
101. Zhu H, Tannous P, Johnstone JL, et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest 2007; 117: 1782–1793.
102. Kanamori H, Takemura G, Goto K, et al. Autophagy limits acute myocardial infarction induced by permanent coronary artery occlusion. Am J Physiol Heart Circ Physiol 2011; 300: H2261–2271.
103. Cao DJ, Wang ZV, Battiprolu PK, et al. Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc Natl Acad Sci U S A 2011; 108: 4123–4128.
104. Ma X, Liu H, Foyil SR, et al. Impaired autophagosome clearance contributes to cardiomyocyte death in ischemia/reperfusion injury. Circulation 2012; 125: 3170–3181.
105. Martinez NJ, Gregory RI. Argonaute2 expression is post-transcriptionally coupled to microRNA abundance. RNA 2013; 19: 605–612.
106. Smibert P, Yang J-S, Azzam G, Liu J-L, Lai EC. Homeostatic control of Argonaute stability by microRNA availability. Nat Struct Mol Biol 2013; 20: 789–795.
107. Drews O, Taegtmeyer H. Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies. Antioxid Redox Signal 2014; 21: 2322–2343.
108. Powell SR, Herrmann J, Lerman A, Patterson C, Wang X. The ubiquitin-proteasome system and cardiovascular disease. Prog Mol Biol Transl Sci 2012; 109: 295–346.
109. Wang X, Robbins J. Proteasomal and lysosomal protein degradation and heart disease. J Mol Cell Cardiol 2014; 71: 16–24.
110. Calise J, Powell SR. The ubiquitin proteasome system and myocardial ischemia. Am J Physiol Heart Circ Physiol 2013; 304: H337–349.
111. Rau F, Freyermuth F, Fugier C, et al. Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy. Nat Struct Mol Biol 2011; 18: 840–845.
112. Newman MA, Thomson JM, Hammond SM. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA 2008; 14: 1539–1549.
113. Hagan JP, Piskounova E, Gregory RI. Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in mouse embryonic stem cells. Nat Struct Mol Biol 2009; 16: 1021–1025.
114. Heo I, Joo C, Kim YK, et al. TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation. Cell 2009; 138: 696–708.
115. Mayr F, Heinemann U. Mechanisms of Lin28-mediated miRNA and mRNA regulation--a structural and functional perspective. Int J Mol Sci 2013; 14: 16532–16553.
116. Ishiura S, Kino Y, Nezu Y, Onishi H, Ohno E, Sasagawa N. Regulation of splicing by MBNL and CELF family of RNA-binding protein. Acta Myol 2005; 24: 74–77.
117. Pascual M, Vicente M, Monferrer L, Artero R. The Muscleblind family of proteins: an emerging class of regulators of developmentally programmed alternative splicing. Differentiation 2006; 74: 65–80.
118. Ho TH, Charlet BN, Poulos MG, Singh G, Swanson MS, Cooper TA. Muscleblind proteins regulate alternative splicing. EMBO J 2004; 23: 3103–3112.
119. Kalsotra A, Xiao X, Ward AJ, et al. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci U S A 2008; 105: 20333–20338.
120. Giudice J, Xia Z, Wang ET, et al. Alternative splicing regulates vesicular trafficking genes in cardiomyocytes during postnatal heart development. Nat Commun 2014; 5: 3603.
121. Koshelev M, Sarma S, Price RE, Wehrens XHT, Cooper TA. Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. Hum Mol Genet 2010; 19: 1066–1075.
122. Lin X, Miller JW, Mankodi A, et al. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet 2006; 15: 2087–2097.
123. Timchenko NA, Patel R, Iakova P, Cai Z-J, Quan L, Timchenko LT. Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis. J Biol Chem 2004; 279: 13129–13139.
124. Ikezoe K, Nakamori M, Furuya H, et al. Endoplasmic reticulum stress in myotonic dystrophy type 1 muscle. Acta Neuropathol 2007; 114: 527–535.
125. Warf MB, Berglund JA. MBNL binds similar RNA structures in the CUG repeats of myotonic dystrophy and its pre-mRNA substrate cardiac troponin T. RNA 2007; 13: 2238–2251.
126. Botta A, Malena A, Loro E, et al. Altered Ca2+ homeostasis and endoplasmic reticulum stress in myotonic dystrophy type 1 muscle cells. Genes (Basel) 2013; 4: 275–292.
127. Kim SH, Kim H-S, Lee M-M. Re-expression of fetal troponin isoforms in the postinfarction failing heart of the rat. Circ J 2002; 66: 959–964.
128. Onishi H, Kino Y, Morita T, Futai E, Sasagawa N, Ishiura S. MBNL1 associates with YB-1 in cytoplasmic stress granules. J Neurosci Res 2008; 86: 1994–2002.
129. Gommans WM. A-to-I editing of microRNAs: regulating the regulators? Semin Cell Dev Biol 2012; 23: 251–257.
130. Luciano DJ, Mirsky H, Vendetti NJ, Maas S. RNA editing of a miRNA precursor. RNA 2004; 10: 1174–1177.
131. Yang W, Chendrimada TP, Wang Q, et al. Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat Struct Mol Biol 2006; 13: 13–21.
132. Weissbach R, Scadden ADJ. Tudor-SN and ADAR1 are components of cytoplasmic stress granules. RNA 2012; 18: 462–471.
133. Wang Q, Miyakoda M, Yang W, et al. Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. J Biol Chem 2004; 279: 4952–4961.
134. Hassler J, Cao SS, Kaufman RJ. IRE1, a double-edged sword in pre-miRNA slicing and cell death. Dev Cell 2012; 23: 921–923.
135. Upton JP, Wang L, Han D, et al. IRE1alpha cleaves select microRNAs during ER stress to derepress translation of proapoptotic Caspase-2. Science 2012; 338: 818–822.
136. Suzuki HI, Arase M, Matsuyama H, et al. MCPIP1 ribonuclease antagonizes dicer and terminates microRNA biogenesis through precursor microRNA degradation. Mol Cell 2011; 44: 424–436.
137. Cifuentes RA, Cruz-Tapias P, Rojas-Villarraga A, Anaya J-M. ZC3H12A (MCPIP1): molecular characteristics and clinical implications. Clin Chim Acta 2010; 411: 1862–1868.
138. Azfer A, Niu J, Rogers LM, Adamski FM, Kolattukudy PE. Activation of endoplasmic reticulum stress response during the development of ischemic heart disease. Am J Physiol Heart Circ Physiol 2006; 291: H1411–H1420.
139. Liang J, Saad Y, Lei T, et al. MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-kappaB signaling. J Exp Med 2010; 207: 2959–2973.
140. Roy A, Kolattukudy PE. Monocyte chemotactic protein-induced protein (MCPIP) promotes inflammatory angiogenesis via sequential induction of oxidative stress, endoplasmic reticulum stress and autophagy. Cell Signal 2012; 24: 2123–2131.
141. Younce C, Kolattukudy P. MCP-1 induced protein promotes adipogenesis via oxidative stress, endoplasmic reticulum stress and autophagy. Cell Physiol Biochem 2012; 30: 307–320.
142. Younce CW, Wang K, Kolattukudy PE. Hyperglycaemia-induced cardiomyocyte death is mediated via MCP-1 production and induction of a novel zinc-finger protein MCPIP. Cardiovasc Res 2010; 87: 665–674.
143. Qi D, Huang S, Miao R, et al. Monocyte chemotactic protein-induced protein 1 (MCPIP1) suppresses stress granule formation and determines apoptosis under stress. J Biol Chem 2011; 286: 41692–41700.
144. Rao RV, Ellerby HM, Bredesen DE. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ 2004; 11: 372–380.
145. Dosenko VE, Gurianova VL, Surova OV, Stroy DA, Moibenko AA. Mature and immature microRNA ratios in cultured rat cardiomyocytes during anoxia-reoxygenation. Exp Clin Cardiol 2012; 17: 84–87.
146. Tsimokha AS, Kulichkova VA, Karpova EV, et al. DNA damage modulates interactions between microRNAs and the 26S proteasome. Oncotarget 2014; 5: 3555–3567.
147. Gurianova V, Stroy D, Kruzliak P, Kyrichenko V, Moibenko A, Dosenko V. Does proteasome regulate the level of microRNA-1 in cardiomyocytes? Application to anoxia-reoxygenation. Mol Cell Biochem 2015; 404: 45–51.
148. Petit F, Jarrousse AS, Boissonnet G, et al. Proteasome (prosome) associated endonuclease activity. Mol Biol Rep 1997; 24: 113–117.
149. Petit F, Jarrousse AS, Dahlmann B et al. Involvement of proteasomal subunits zeta and iota in RNA degradation. Biochem J 1997; 326(Pt 1): 93–98.
150. Schmid HP, Pouch MN, Petit F, et al. Relationships between proteasomes and RNA. Mol Biol Rep 1995; 21: 43–47.
151. Ballut L, Petit F, Mouzeyar S, et al. Biochemical identification of proteasome-associated endonuclease activity in sunflower. Biochim Biophys Acta 2003; 1645: 30–39.
152. Jarrousse AS, Petit F, Kreutzer-Schmid C, Gaedigk R, Schmid HP. Possible involvement of proteasomes (prosomes) in AUUUA-mediated mRNA decay. J Biol Chem 1999; 274: 5925–5930.
153. Kulichkova VA, Tsimokha AS, Fedorova OA, et al. 26S proteasome exhibits endoribonuclease activity controlled by extra-cellular stimuli. Cell Cycle 2010; 9: 840–849.
154. Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28. Science 2008; 320: 97–100.
155. Suh N, Baehner L, Moltzahn F, et al. MicroRNA function is globally suppressed in mouse oocytes and early embryos. Curr Biol 2010; 20: 271–277.
156. Thomson JM, Newman M, Parker JS, Morin-Kensicki EM, Wright T, Hammond SM. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev 2006; 20: 2202–2207.
157. Granger A, Abdullah I, Huebner F, et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J 2008; 22: 3549–3560.
158. Aune SE, Herr DJ, Mani SK, Menick DR. Selective inhibition of class I but not class IIb histone deacetylases exerts cardiac protection from ischemia reperfusion. J Mol Cell Cardiol 2014; 72: 138–145.
159. Xie M, Kong Y, Tan W, et al. Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. Circulation 2014; 129: 1139–1151.
160. Zhang Y, Ren J. Targeting autophagy for the therapeutic application of histone deacetylase inhibitors in ischemia/reperfusion heart injury. Circulation 2014; 129: 1088–1091.
161. Hoxha E, Lambers E, Xie H, et al. Histone deacetylase 1 deficiency impairs differentiation and electrophysiological properties of cardiomyocytes derived from induced pluripotent cells. Stem Cells 2012; 30: 2412–2422.
162. Montgomery RL, Davis CA, Potthoff MJ, et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 2007; 21: 1790–1802.